OBJECTIVE To compare the efficacy and safety of tildrakizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis. METHODS A retrospective analysis was conducted on 141 patients with moderate-to-severe plaque psoriasis treated at the First Affiliated Hospital of Nanyang Medical College from January 2024 to April 2025. According to the treatment regimen，the patients were divided into tildrakizumab g roup （ n ＝61） and secukinumab group （ n ＝80）. The PASI 75，PASI 90，and PASI 100 response rates， the Psoriasis Area and Severity Index （PASI） and Dermatology Life Quality Index （DLQI） scores， skin barrier function （sebum content and stratum corneum water content）， inflammatory factor levels [interleukin-17 （IL-17）， tumor necrosis factor-α （TNF-α）， and IL-23 ] before and after treatment， and the incidence of adverse drug reactions during treatment were compared between the two groups. RESULTS After 12 weeks of treatment， the PASI 75， PASI 90， and PASI 100 response rates in the tildrakizumab group were significantly higher than those in the secukinumab group （ P ＜0.05）. After treatment， PASI and DLQI scores as well as serum levels of IL-17， TNF-α， and IL-23 in both groups were significantly reduced compared to before treatment in the same group； sebum content and stratum corneum water content were significantly increased compared to before treatment in the same group （ P ＜0.05）； the tildrakizumab group showed better results than the secukinumab group （ P ＜0.05）. The overall incidence of adverse drug reactions was also significantly lower in the tildrakizumab group compared with the secukinumab group （ P ＜0.05）. CONCLUSIONS Compared with secukinumab， tildrakizumab demonstrates superior efficacy in the treatment of moderate-to-severe plaque psoriasis， providing improved symptom relief， enhanced skin barrier function， reduced levels of inflammatory factors， and higher safety.

Objective To investigate the effect of L-carnifine on the anemia of renal anemia and its effect on endothelin and left ventricular remodeling in maintenance hemodialysis patients.Methods 206 patients with uremia who underwent hemodialysis for more than 6 months from November 2010 to November 2014 were randomly divided into study group and control group (n =103),control group (n =103).Patients in the study group were treated with intravenous injection of levocarnitine injection on the basis of the control group.After 6 months of treatment,the clinical curative effect of the two groups was observed.Results After treatment,the levels of Hb and HCT were significantly increased,ET levels were significantly reduced,in which the change of patients in the study group was significantly better than the control group (P ＜ 0.05);LAD,LVDs and LVDd of the two groups were different (P ＜ 0.05).The difference between the two groups was statistically significant (P ＜ 0.05).Conclusion L-carnitine combined with erythropoietin in the treatment of renal hemodialysis patients with renal anemia can improve the therapeutic effect,reduce plasma endothelin levels,effectively improve or inhibit the occurrence and development of left ventricular remodeling,effective prevention of heart failure,The effect is remarkable,can promote the use.